Response to Adjuvant Therapy of Granulomatous Lymphadenitis: Evidence from High Burden Country

Article Sidebar

PDF
Published: Dec 9, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i12-17
Keywords:
Adjuvant Therapy Granulomatous Lymphadenitis Tuberculosis

Main Article Content

Muhammad Yamsun
Department of Surgery, Sub-Oncology, Faculty of Medicine, Universitas Jenderal Soedirman, Purwokerto
Husnan Mujiburrahman
GP at RSU Wiradadi Husada, Banyumas
Kamal Agung Wijayana
Department of Sub-Digestive Surgery, Faculty of Medicine, Universitas Jenderal Sudirman, Purwokerto
Fiqham Muhamad
Medical Student at Faculty of Medicine, Universitas Jenderal Sudirman, Purwokerto

Abstract

Introduction: A granulomatous lymphadenitis is a form of inflammation of the lymph nodes that are often found. Until now, effective treatment of granulomatous lymphadenitis is still inconsistent, namely between surgical intervention, antibiotics, or adjuvant therapy.


Objective: This study aims to determine the response to adjuvant therapy in patients with granulomatous lymphadenitis at RSUD Prof. Dr. Margono Soekarjo in 2019 – 2020.


Methods: The research was a descriptive observational study with a retrospective approach that used secondary data from the medical records of the polyclinic and inpatient ward of RSUD Prof. Dr. Margono Soekarjo Purwokerto. 


Results: A total of 5 patients with tuberculous granulomatous lymphadenitis (66,7%) experienced a complete response to therapy after surgical excision followed by administration of anti-tuberculosis adjuvants an average of 6,5 ± 3,6 times and a mean duration of administration of 22,5 ± 14,7 weeks. A total of 14 patients with non-tuberculous granulomatous lymphadenitis (73,7%) experienced a complete response to therapy after surgical excision, incision drainage followed by adjuvant antibiotic therapy alone or in combination with 1-3 times and the median duration of administration was 3,5 weeks.


Conclusion: Surgical excision followed by adjuvant therapy in tuberculous and non-tuberculous granulomatous lymphadenitis has good cure rates.

Article Details

How to Cite
Yamsun, M. ., Mujiburrahman, H. ., Wijayana, K. A. ., & Muhamad, F. . (2022). Response to Adjuvant Therapy of Granulomatous Lymphadenitis: Evidence from High Burden Country . International Journal of Medical Science and Clinical Research Studies, 2(12), 1458–1462. https://doi.org/10.47191/ijmscrs/v2-i12-17
Issue
Vol. 2 No. 12 (2022): Volume 02 Issue 12 December 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. V. Kumar, A. K. Abbas, and J. C. Aster, Robbins basic pathology e-book. Elsevier Health Sciences, 2017.

II. Q. Neven, D. Van der Linden, M. Hainaut, and S. Schmitz, “Long-term outcome of surgical excision for treatment of cervicofacial granulomatous lymphadenitis in children,” Eur. Arch. Oto-Rhino-Laryngology, vol. 277, no. 6, pp. 1785–1792, 2020.

III. M. Ismail and M. Muhammad, “FREQUENCY OF TUBERCULOSIS IN CERVICAL LYMPHADENOPATHY.,” JPMI J. Postgrad. Med. Inst., vol. 27, no. 3, 2013.

IV. W. H. Organization, “WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021–2025: background document,” 2021.

V. W. Assefa, T. Eshete, Y. Solomon, and B. Kassaye, “Clinicoepidemiologic considerations in the diagnosis of tuberculous lymphadenitis: evidence from a high burden country,” Int. J. Infect. Dis., vol. 124, pp. 152–156, 2022, doi: https://doi.org/10.1016/j.ijid.2022.09.030.

VI. J. Chakaya et al., “Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts,” Int. J. Infect. Dis., vol. 113, pp. S7–S12, 2021, doi: https://doi.org/10.1016/j.ijid.2021.02.107.

VII. I. Agatha and G. N. P. Mandela, “Uji Klinis Sindroma Klinis Limfadenitis Tuberkulosis Dengan Fine Needle Aspiration Biopsy (Fnab) Sebagai Baku Emas,” E-Jurnal Med. Udayana, 2016.

VIII. G. Karanis and P. Karanis, “Tuberculosis: Epidemiology and Global Impact, Including Extrapulmonary Tuberculosis Manifestation With Emphasis on Skeletal Tuberculosis and a Rare Example of Shoulder Tuberculosis From Tibetan Plateau Area,” in Encyclopedia of Environmental Health (Second Edition), Second Edi., J. Nriagu, Ed. Oxford: Elsevier, 2019, pp. 135–160. doi: https://doi.org/10.1016/B978-0-12-409548-9.11244-8.

IX. A. Luong, J. E. McClay, H. S. Jafri, and O. Brown, “Antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis,” Laryngoscope, vol. 115, no. 10, pp. 1746–1751, 2005.

X. A. Zeharia, T. Eidlitz-Markus, Y. Haimi-Cohen, Z. Samra, L. Kaufman, and J. Amir, “Management of nontuberculous mycobacteria-induced cervical lymphadenitis with observation alone,” Pediatr. Infect. Dis. J., vol. 27, no. 10, pp. 920–922, 2008.

XI. V. Koo, T. F. Lioe, and R. A. J. Spence, “Fine needle aspiration cytology (FNAC) in the diagnosis of granulomatous lymphadenitis,” Ulster Med. J., vol. 75, no. 1, p. 59, 2006.

XII. R. I. Depkes, “Kategori umur,” Dalam http//kategori-umur-menurut-depkes. html. Diakses pada tanggal, vol. 30, 2009.

XIII. J.-M. Fontanilla, A. Barnes, and C. F. Von Reyn, “Current diagnosis and management of peripheral tuberculous lymphadenitis,” Clin. Infect. Dis., vol. 53, no. 6, pp. 555–562, 2011.

XIV. V. A. C. M. Koeken et al., “BCG vaccination in humans inhibits systemic inflammation in a sex-dependent manner,” J. Clin. Invest., vol. 130, no. 10, pp. 5591–5602, 2020.